Literature DB >> 23341459

Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells.

Morgane Gourlaouen1, Jonathan C Welti1, Naveen S Vasudev1, Andrew R Reynolds2.   

Abstract

Vascular endothelial growth factor (VEGF) stimulates angiogenesis by binding to VEGF receptor 2 (VEGFR2) on endothelial cells (ECs). Downstream activation of the extracellular related kinases 1/2 (ERK1/2) is important for angiogenesis to proceed. Receptor internalization has been implicated in VEGFR2 signaling, but its role in the activation of ERK1/2 is unclear. To explore this question we utilized pitstop and dynasore, two small molecule inhibitors of endocytosis. First, we confirmed that both inhibitors block the internalization of VEGFR2 in ECs. We then stimulated ECs with VEGF in the presence and absence of the inhibitors and examined VEGFR2 signaling to ERK1/2. Activation of VEGFR2 and C-Raf still occurred in the presence of the inhibitors, whereas the activation of MEK1/2 and ERK1/2 was abrogated. Therefore, although internalization is not required for activation of either VEGFR2 or C-Raf in ECs stimulated with VEGF, internalization is necessary to activate the more distal kinases in the cascade. Importantly, inhibition of internalization also prevented activation of ERK1/2 when ECs were stimulated with other pro-angiogenic growth factors, namely fibroblast growth factor 2 and hepatocyte growth factor. In contrast, the same inhibitors did not block ERK1/2 activation in fibroblasts or cancer cells stimulated with growth factors. Finally, we show that these small molecule inhibitors of endocytosis block angiogenesis in vitro and in vivo. Therefore, receptor internalization may be a generic requirement for pro-angiogenic growth factors to activate ERK1/2 signaling in human ECs, and targeting receptor trafficking may present a therapeutic opportunity to block tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23341459      PMCID: PMC3597788          DOI: 10.1074/jbc.M112.446401

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

Review 1.  VEGF receptor signalling - in control of vascular function.

Authors:  Anna-Karin Olsson; Anna Dimberg; Johan Kreuger; Lena Claesson-Welsh
Journal:  Nat Rev Mol Cell Biol       Date:  2006-05       Impact factor: 94.444

2.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

3.  Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

Authors:  Razelle Kurzrock; Steven I Sherman; Douglas W Ball; Arlene A Forastiere; Roger B Cohen; Ranee Mehra; David G Pfister; Ezra E W Cohen; Linda Janisch; Forlisa Nauling; David S Hong; Chaan S Ng; Lei Ye; Robert F Gagel; John Frye; Thomas Müller; Mark J Ratain; Ravi Salgia
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

4.  Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis.

Authors:  Lars Jakobsson; Johan Kreuger; Katarina Holmborn; Lars Lundin; Inger Eriksson; Lena Kjellén; Lena Claesson-Welsh
Journal:  Dev Cell       Date:  2006-05       Impact factor: 12.270

Review 5.  Controlling escape from angiogenesis inhibitors.

Authors:  Barbara Sennino; Donald M McDonald
Journal:  Nat Rev Cancer       Date:  2012-10       Impact factor: 60.716

Review 6.  VEGF-targeted therapy: mechanisms of anti-tumour activity.

Authors:  Lee M Ellis; Daniel J Hicklin
Journal:  Nat Rev Cancer       Date:  2008-07-03       Impact factor: 60.716

7.  Tumor regression by targeted gene delivery to the neovasculature.

Authors:  John D Hood; Mark Bednarski; Ricardo Frausto; Samira Guccione; Ralph A Reisfeld; Rong Xiang; David A Cheresh
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

Review 8.  Resistance to targeted therapy in renal-cell carcinoma.

Authors:  Brian I Rini; Michael B Atkins
Journal:  Lancet Oncol       Date:  2009-10       Impact factor: 41.316

9.  Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation.

Authors:  Rodney B Luwor; Xiaowen Chin; Andrew B McGeachie; Phillip J Robinson; Hong-Jian Zhu
Journal:  Growth Factors       Date:  2012-05-11       Impact factor: 2.511

10.  Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth.

Authors:  F Bussolino; M F Di Renzo; M Ziche; E Bocchietto; M Olivero; L Naldini; G Gaudino; L Tamagnone; A Coffer; P M Comoglio
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

View more
  30 in total

1.  Constitutive Endocytosis of VEGFR2 Protects the Receptor against Shedding.

Authors:  Dimitris Basagiannis; Savvas Christoforidis
Journal:  J Biol Chem       Date:  2016-06-13       Impact factor: 5.157

2.  Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.

Authors:  Ming-Jer Hsieh; Hsien-Ta Liu; Chao-Nin Wang; Hsiu-Yun Huang; Yuling Lin; Yu-Shien Ko; Jong-Shyan Wang; Vincent Hung-Shu Chang; Jong-Hwei S Pang
Journal:  J Mol Med (Berl)       Date:  2016-11-15       Impact factor: 4.599

Review 3.  Receptor tyrosine kinases endocytosis in endothelium: biology and signaling.

Authors:  Xi Zhang; Michael Simons
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-06-12       Impact factor: 8.311

4.  Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells.

Authors:  R Eguchi; T Nakano; I Wakabayashi
Journal:  Oncogene       Date:  2016-06-27       Impact factor: 9.867

5.  Dynamin 2 regulation of integrin endocytosis, but not VEGF signaling, is crucial for developmental angiogenesis.

Authors:  Monica Y Lee; Athanasia Skoura; Eon Joo Park; Shira Landskroner-Eiger; Levente Jozsef; Amelia K Luciano; Takahisa Murata; Satish Pasula; Yunzhou Dong; Mohamed Bouaouina; David A Calderwood; Shawn M Ferguson; Pietro De Camilli; William C Sessa
Journal:  Development       Date:  2014-03-05       Impact factor: 6.868

6.  Chemical Inhibitors of Dynamin Exert Differential Effects in VEGF Signaling.

Authors:  Dimitris Basagiannis; Sofia Zografou; Evangeli Goula; Despoina Gkeka; Evangelos Kolettas; Savvas Christoforidis
Journal:  Cells       Date:  2021-04-23       Impact factor: 6.600

7.  The Cell Adhesion Molecule Necl-4/CADM4 Serves as a Novel Regulator for Contact Inhibition of Cell Movement and Proliferation.

Authors:  Shota Yamana; Amina Tokiyama; Kiyohito Mizutani; Ken-ichi Hirata; Yoshimi Takai; Yoshiyuki Rikitake
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

8.  Glioma cell proliferation controlled by ERK activity-dependent surface expression of PDGFRA.

Authors:  Dongfeng Chen; Duo Zuo; Cheng Luan; Min Liu; Manli Na; Liang Ran; Yingyu Sun; Annette Persson; Elisabet Englund; Leif G Salford; Erik Renström; Xiaolong Fan; Enming Zhang
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

9.  FGF21 promotes endothelial cell angiogenesis through a dynamin-2 and Rab5 dependent pathway.

Authors:  Usman Yaqoob; Kumaravelu Jagavelu; Uday Shergill; Thiago de Assuncao; Sheng Cao; Vijay H Shah
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

Review 10.  Tuning cellular responses to BMP-2 with material surfaces.

Authors:  Elisa Migliorini; Anne Valat; Catherine Picart; Elisabetta Ada Cavalcanti-Adam
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-03       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.